104 related articles for article (PubMed ID: 21358294)
1. Lymphocyte-predominant Hodgkin disease: a comprehensive overview.
Bose S; Ganesan C; Pant M; Lai C; Tabbara IA
Am J Clin Oncol; 2013 Feb; 36(1):91-6. PubMed ID: 21358294
[TBL] [Abstract][Full Text] [Related]
2. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Hawkes EA; Wotherspoon A; Cunningham D
Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
[TBL] [Abstract][Full Text] [Related]
3. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
4. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
5. Nodular lymphocyte predominant Hodgkin lymphoma.
Lee AI; LaCasce AS
Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
[TBL] [Abstract][Full Text] [Related]
6. Modern management of lymphocyte-predominant Hodgkin lymphoma.
Xing KH; Savage KJ
Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
[TBL] [Abstract][Full Text] [Related]
7. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
8. Nodular lymphocyte-predominant hodgkin lymphoma.
Tsai HK; Mauch PM
Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
[TBL] [Abstract][Full Text] [Related]
9. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.
Shankar A; Daw S
Br J Haematol; 2012 Nov; 159(3):288-98. PubMed ID: 22994199
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
[TBL] [Abstract][Full Text] [Related]
12. Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome.
Carbone A; Spina M; Gloghini A; Ponzoni M; Doglioni C; Tirelli U
Am J Hematol; 2013 Feb; 88(2):161-2. PubMed ID: 23349009
[No Abstract] [Full Text] [Related]
13. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.
McKay P; Fielding P; Gallop-Evans E; Hall GW; Lambert J; Leach M; Marafioti T; McNamara C;
Br J Haematol; 2016 Jan; 172(1):32-43. PubMed ID: 26538004
[No Abstract] [Full Text] [Related]
14. Optimal treatment for relapsing patients with Hodgkin lymphoma.
Sibon D; Brice P
Expert Rev Hematol; 2009 Jun; 2(3):285-95. PubMed ID: 21082970
[TBL] [Abstract][Full Text] [Related]
15. Managing relapsed and refractory Hodgkin lymphoma.
Brice P
Br J Haematol; 2008 Apr; 141(1):3-13. PubMed ID: 18279457
[TBL] [Abstract][Full Text] [Related]
16. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.
Daw S; Wynn R; Wallace H
Br J Haematol; 2011 Feb; 152(3):249-60. PubMed ID: 21133886
[TBL] [Abstract][Full Text] [Related]
17. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
[TBL] [Abstract][Full Text] [Related]
18. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
[TBL] [Abstract][Full Text] [Related]
19. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
[TBL] [Abstract][Full Text] [Related]
20. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation.
Couronné L; Schneider P; Picquenot JM; Laberge S; Bastard C; Vannier JP
J Pediatr Hematol Oncol; 2008 Dec; 30(12):959-62. PubMed ID: 19131792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]